Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,532 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer (Diagnosis) Clear all
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

NCT00329797
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D
Dietary Supplement · Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
80
States / cities
Chico, California • Los Angeles, California • Pomona, California + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jun 26, 2026, 12:37 AM EDT
Withdrawn No phase listed Observational

Investigation of Protein Biomarkers of Prostate Cancer

NCT00323180
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jun 26, 2026, 12:37 AM EDT
Active, not recruiting Early Phase 1 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

NCT05851365
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Hyperpolarized Bicarbonate (13C), Magnetic Resonance imaging
Drug · Procedure
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Hemorrhagic Radiation Proctitis Using the Halo System

NCT01103492
View directory record Official record
Conditions
Pelvic Neoplasms
Interventions
HALO90 Ablation catheter
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Jun 26, 2026, 12:37 AM EDT
Not listed No phase listed Observational

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

NCT04100811
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
miR Scientific LLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
2,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Stockbridge, Georgia • Farmingdale, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

NCT00001444
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Neoplasm, Prostatic Neoplasm
Interventions
7-hydroxystaurosporine (UCN-01)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 1 Interventional

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

NCT03454451
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jun 26, 2026, 12:37 AM EDT
Active, not recruiting No phase listed Observational

Digitally Captured Activity Data and PROs to Monitor Physical Function in Prostate Cancer Patients

NCT04575402
View directory record Official record
Conditions
Prostate Cancer
Interventions
Wearable Activity Monitor
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 1Phase 2 Interventional

MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

NCT00070837
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MLN2704 (DM1 conjugated monoclonal antibody MLN591)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2007 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

NCT00974311
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Jun 26, 2026, 12:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness

NCT05968144
View directory record Official record
Conditions
Prostatic Neoplasm, Survivorship, Frailty, Aging, Metastatic Breast Cancer
Interventions
Dietary recommendations, Time-restricted eating
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Not applicable Interventional

Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks

NCT01844999
View directory record Official record
Conditions
Prostate Cancer
Interventions
Personal Patient Profile - Prostate (P3P), Standard prostate cancer information websites
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Downey, California • Los Angeles, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jun 26, 2026, 12:37 AM EDT
Recruiting Not applicable Interventional

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

NCT06465966
View directory record Official record
Conditions
Prostate Cancer
Interventions
iRAI
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

NCT00003819
View directory record Official record
Conditions
Prostate Cancer
Interventions
QS21, TF(c)-KLH conjugate vaccine, Thomsen-Friedenreich antigen, keyhole limpet hemocyanin
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Jun 26, 2026, 12:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

NCT03317392
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Olaparib, Quality-of-Life Assessment, Radium Ra 223 Dichloride
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
La Jolla, California • Sacramento, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

NCT00683475
View directory record Official record
Conditions
Prostate Cancer
Interventions
IMC-A12, Mitoxantrone, Prednisone, IMC-1121B (ramucirumab)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Jun 26, 2026, 12:37 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04631601
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Acapatamab, Enzalutamide, Abiraterone, AMG 404
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CP-751,871, docetaxel, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Jun 26, 2026, 12:37 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate

NCT00691977
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy followed by prostatectomy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 69 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Jun 26, 2026, 12:37 AM EDT
Completed No phase listed Observational

Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy

NCT01143467
View directory record Official record
Conditions
Cancer, Fatigue
Interventions
Not listed
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jun 26, 2026, 12:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Plant-based Diets and Risk of Cancer in the Adventist Health Study-2

NCT03615599
View directory record Official record
Conditions
Cancer, Breast, Cancer, Colorectal, Cancer, Prostate
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
30 Years and older
Enrollment
96,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2028
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 2 Interventional

Brachytherapy in Treating Patients With Prostate Cancer

NCT00003312
View directory record Official record
Conditions
Prostate Cancer
Interventions
iodine I 125
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jun 26, 2026, 12:37 AM EDT
Completed No phase listed Observational

Active Surveillance in Prostate Cancer

NCT00490763
View directory record Official record
Conditions
Prostate Cancer
Interventions
Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 26, 2026, 12:37 AM EDT
Terminated Phase 2 Interventional

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

NCT00383487
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
Calcitriol, Naproxen-n-butyl nitrate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Jun 26, 2026, 12:37 AM EDT